Table 5. Second- and third-line therapy following SCOUT.
| Regimen | No. of patients, n (%), at all doses (N=45) | No. of patients, n (%), at MTD (N=29) |
|---|---|---|
| Second-line therapy | ||
| Eligible for second-line therapya | 36 | 24 |
| Resumed SCOUT | 12 (33) | 9 (38) |
| Mitomycin C/capecitabine | 3 (8) | 2 (8) |
| Irinotecan/cetuximab | 3 (8) | 3 (13) |
| Oxaliplatin/modified de Gramont | 1 (3) | 1 (4) |
| Oxaliplatin/capecitabine | 1 (3) | 0 |
| Capecitabine | 1 (3) | 0 |
| Phase I trial | 3 (8) | 3 (13) |
| Unfit for further chemotherapy | 12 (33) | 6 (25) |
|
No. of patients at all doses (N=45)
|
||
| Third-line therapy | ||
| Second-line SCOUT patients eligible for third-line therapyb | 12 | |
| Resumed SCOUT | 2 | |
| Mitomycin C/capecitabine | 1 | |
| Irinotecan/cetuximab | 1 | |
| Capecitabine | 1 | |
| Phase I trial | 4 | |
| Unfit for further chemotherapy | 2 | |
| Not progressed on second-line therapy | 1 | |
MTD=maximum tolerated dose.
a
Excludes patients who were not assessable for progression and those who had not progressed at the time of the analysis.
b
Patients who received SCOUT as second-line therapy and were considered eligible for further treatment; excludes patients who had second-line treatments other than SCOUT.